Patient Technology Implementation Framework

What is the Patient Technology Implementation Framework?

The Implementation Framework outlines a holistic approach for Sponsors to adopt Patient Technology (PT) within their own organizations. The Framework encourages a mindset of strategic thinking, rapid learning, and patient-centric design when Sponsors adopt PT.

Access each section by clicking on the navigation buttons below. To return to the PT Solutions, click here.

Use Case Ideation Technology Proof of Concept Use Case Development Technology Pilot Experimentation Strategy Development Expansion
Experimentation Click to Expand Expansion Strategy Development

Strategy Development

Stage Definition

Develop a company-level strategy that outlines an internal approach to adopt Patient Technologies for specific technology types, therapeutic areas, or teams/functions, with defined program goals.

Approach

Determine goals for scaled PT at the company, program, therapeutic area, and technology level

  • Evaluate the landscape (Landscapes may include company goals, pipeline or strategy, patient priorities, academic research, competitive efforts, technology offerings, regulatory considerations, internal knowledge, precedence, site sentiment, etc.)
  • Identify the organization’s primary objectives for implementing PT. Clearly define the challenge the PT should address and the benefit it should bring. Ensure they are in line with organization strategy
  • Clearly define desired benefits to patients, study programs, or other stakeholders. Engage patients or other stakeholders to establish goals, priorities, and value propositions as needed
  • Identify key risks, knowns, and unknowns

Develop business case and/or a business case development plan at the program level

  • Outline value proposition, risks, and costs
  • Consider current status and future goals
  • Identify unknowns and data required to develop a business case
  • Define measurable endpoints and KPIs with respect to overall program goals
  • Define metrics that teams can use in individual studies to contribute to the overall business case
  • Develop plan to track and refine business case over time

Develop implementation strategy at the program level

  • Evaluate potential impacts of the PT program on study design (e.g., costs, sourcing, timing, etc.)
  • Identify target segments for use of PT (e.g., therapeutic areas, patient populations, geographic regions). Identify stakeholders and the engagements or inputs required with each
  • Identify challenges or risks to adopting PT in the program (e.g., unknowns, risks, costs, timing, patient and other stakeholder burdens, resource gaps, organizational barriers). Engage study teams and other stakeholders as applicable
  • Develop a plan to address risks and unknowns through additional research, collaborations, proof of concept development, studies, or through other engagement activities (e.g., regulatory or patient engagement)
  • Develop guidelines for study teams to coordinate PT implementation & pilot design across studies
Discussion Guide

The considerations listed here are intended to help identify risks and unknowns, plus provide a list of internal stakeholders typically able to offer insight or expertise. Please note, the provided list of considerations is not all-encompassing.

As internal department names vary greatly from one company to the next, some of the listed stakeholders may not be self-explanatory. Below, you will find a short description of the more ambiguous groups:

Internal StakeholderDescription
Clinical Technologies SMEs for clinical technologies, vendor relations and vendor management, technology scouting, implementation strategies as well as implementation leadership and guidance.
Medical Medical or clinical SMEs for given indications and/or therapeutic areas.
Patient Engagement SMEs or groups assisting with patient advisory boards, patient engagement and retention strategies, patient centricity assessments and/or patient centric strategies.
Quality SMEs for qualification, testing and validation activities, processes, (vendor) audits, documentation and GxP compliance.

Other, more universally understood, stakeholders referenced include Data Management, Functional Leadership, Human Resources, IT, Legal, Procurement, Regulatory Affairs, Site Relations, and Study Teams.

Budget & Resourcing

Consideration
Internal Stakeholders
Are sufficient resources available to support use of the PT? Are additional and/or specialist resources needed? Should these be internal or external? When evaluating existing resources, consider qualifications as well as conflicting workload.
Functional Leadership, Human Resources, Procurement
Will the PT require additions or changes to internal infrastructure or IT systems? Is this cost accounted for?
Clinical Technologies, IT
Will use of the PT warrant or require increased monitoring? Are such additional monitoring resources available?
Human Resources, Study Teams

Process & Strategy

Consideration
Internal Stakeholders
Are you following all applicable SOPs? Are the SOPs fit for purpose?
Quality
Are the right stakeholders involved in vendor evaluations and a go/no-go decision?
*
Is the PT specific to a given project or to be used broadly across the platform/portfolio?
Clinical Technologies, Study Teams
Are the PT and implementation strategy aligned with the overarching company strategy? E.g. insourcing vs. outsourcing, build vs. buy, …
IT
Are you accounting for feedback, expertise and best practices as part of your design and plans for PT use? This may include vendor expertise, industry experience and guidelines, site feedback, prior experience within your company, …
Clinical Technologies, Study Teams
Will you be conducting follow-up interviews and/or lessons learned sessions? How will you incorporate insights and lessons learned into future work? Is there a formal mechanism for knowledge-sharing in place?
Study Teams

Technology & Infrastructure

Consideration
Internal Stakeholders
Can the PT be integrated into existing company systems and architecture or will amendments have to be made?
Clinical Technologies, Data Management, IT

Use Case Ideation

Stage Definition

Identify potential use cases, technologies, and endpoints for additional development, and identify implementation approaches for PT within a study or related series of studies.

Approach

Brainstorm problem statements, research questions, and desired value

  • What do you want to achieve, why do you want to achieve it, and why/how can PT help you achieve it?
  • Consider goals and impacts from an organizational perspective, program perspective, patient perspective, etc.

Understand the Landscape – Both internal and external

Past Work and Organizational Landscape

  • What has been done in the past, either internally or externally in industry or academia?
  • What were the reasons for success and failure?
  • What is known about patient needs, priorities, and burdens?
  • What does meaningful change look like to these patients?
  • Pursue engagements as necessary
  • What experiences/capabilities exist within the company?
  • Identify learnings from past work and gaps (e.g., processes, resources, expertise) that must still be addressed. Should these gaps be filled internally, or should they be outsourced?

Technical Landscape

  • What tools, technologies, and vendors exist?
  • What is technologically feasible?
  • What internal development or infrastructure might be required?

Strategic Alignment & Organizational Support

  • How could a PT program fit into the organization’s strategy and broader body of PT work?
  • Who are the internal and external advocates and opposition?
  • What motivates them?
  • What external initiatives or organizations impact or align with your goals?

Brainstorm solutions, use cases, endpoints, and technologies

  • This brainstorming activity should focus primarily on potential use cases, endpoints, and approaches, rather than specific technology options. In general, this stage and its accompanying activities usually precede the selection of a technology, to ensure the technology is fit for purpose

Refine, Pivot or Proceed

Assess the use cases for theoretical feasibility and alignment with strategy. Based on the landscape assessment, is there potential for any of your use cases to bring the desired value (to the company, to science, to the patients, or otherwise) and address the problem statement you laid out? If so, select one or more of the most promising use cases for additional research and further development.

Discussion Guide

The considerations listed here are intended to help identify risks and unknowns, plus provide a list of internal stakeholders typically able to offer insight or expertise. Please note, the provided list of considerations is not all-encompassing.

As internal department names vary greatly from one company to the next, some of the listed stakeholders may not be self-explanatory. Below, you will find a short description of the more ambiguous groups:

Internal StakeholderDescription
Clinical Technologies SMEs for clinical technologies, vendor relations and vendor management, technology scouting, implementation strategies as well as implementation leadership and guidance.
Medical Medical or clinical SMEs for given indications and/or therapeutic areas.
Patient Engagement SMEs or groups assisting with patient advisory boards, patient engagement and retention strategies, patient centricity assessments and/or patient centric strategies.
Quality SMEs for qualification, testing and validation activities, processes, (vendor) audits, documentation and GxP compliance.

Other, more universally understood, stakeholders referenced include Data Management, Functional Leadership, Human Resources, IT, Legal, Procurement, Regulatory Affairs, Site Relations and Study Teams.

Feasibility & Quality

Consideration
Internal Stakeholders
Have you weighed the benefits and drawbacks of both in-person visits and remote communication methods and agreed when each may be more appropriate?
Clinical Technologies, Patient Engagement
Does use of the PT have a potential impact on other technologies or outcomes measured? E.g. device weight causing fatigue, …
Clinical Technologies, Medical
Has clinical validity been demonstrated between the data generated from the patient technology and the clinical outcome to be studied?
Clinical Technologies

Process & Strategy

Consideration
Internal Stakeholders
Are the right stakeholders involved in vendor evaluations and a go/no-go decision?
*
Is the PT specific to a given project or to be used broadly across the platform/portfolio?
Clinical Technologies, Study Teams

Technology & Infrastructure

Considerations
Internal Stakeholders
Can the PT be integrated into existing company systems and architecture or will amendments have to be made?
Clinical Technologies, Data Management, IT
Will study participants need to/have the option to utilize their own devices (BYOD) or will devices have to be provisioned? If devices have to be provisioned, are supply mechanisms and responsibilities clearly defined?
Clinical Technologies, Procurement, Study Teams
Will the PT require additional setup or infrastructure at sites or patient homes? E.g. configuring or calibrating devices, Wi-Fi hubs, access to patient/site Wi-Fi, cell coverage, special/secure storage, …
Clinical Technologies, IT, Study Teams

Technology Proof of Concept

Stage Definition

Conduct rapid, iterative testing of the PT to understand functionality, ensure fit for purpose, mitigate risks, and determine readiness for a pilot. Address unknowns or risks associated with the PT use case outside of a clinical trial setting.

Approach

Based on the PT Experimentation Plan compiled in the Use Case Development Stage, it may be beneficial to conduct a series of Technology Proofs of Concept to inform technology selection, technology design, pilot design, and scaled implementation. This testing can also be conducted on any training or support materials required for use of the technology. Such assessments should provide high-level or directional information about a PT in the shortest time and at the lowest cost possible.

For the purposes of this framework, ‘Technology Proof of Concept’ includes tests or assessments of a PT that occur outside of a clinical, study, or trial setting. Experimental implementation of a PT in a clinical setting or through studies or trials are categorized as ‘Technology Pilots.’

Types of Proof of Concepts

Gather directional feedback from patients, sites, caregivers, or other stakeholders

  • Methods: Examples include surveys, interviews, advisory boards, market research techniques, and meta-analyses or reviews of past work
  • Goals: Collect guidance or perspectives on direction, privacy, burden, and value; identify factors to consider in future testing; identify health-related factors that may impact PT implementation; etc.

User experience (UX) testing

  • Methods: Examples include usability testing through interviews, field tests, expert reviews, employee volunteers, etc.
  • Goals: Understand user experience and acceptance of the technology; identify specific needs for training or tech support; identify points of confusion or potential opportunities for misuse of the technology; identify issues or required updates of the technology and user interface, etc.

Technical or verification testing of PT

  • Methods: When appropriate, technical assessments can be conducted as a series of rapid tests or experiments that enable technology characterization. It is often valuable to conduct such testing internally to ensure flexibility, develop institutional learning, and gain hands-on experience with the technology
  • Goals: Understand the robustness, accuracy, and maturity of a technology. Assessments may test functionality, connectivity, durability, data quality, accuracy, precision, noise, etc. If more than one technology is being used, ensure interactions between the technologies occur as planned

Analytical Proof of Concept

  • Assess the feasibility of using certain methods, sampling techniques, or endpoints using available datasets from similar technologies. Run proof of concept analyses on these datasets to help refine the direction of PT selection and design, as well as analytical plan development

Mock studies or ‘dry-runs’ of a PT protocol

  • Simulate the implementation of a PT in an internal or non-trial setting to identify and address potential issues prior to implementation in a pilot

What if Proof of Concept Testing is Not Feasible?

  • When testing is not feasible for a specific unknown, identify what will not be tested internally and pursue discussions with the technology’s providers, subject matter experts, or others to assess these features of the PT

Document Learnings

  • Capture both positive and negative insights and use them to refine, improve, or adapt future technology experimentation. Ensure that learnings are shared and accessible to other teams

Understand the Limitations

  • Technology proof of concepts often cannot provide a comprehensive assessment of a technology. Rather, they provide directional insights rapidly to enable better and faster decision- making during technology assessment and design
  • Care should be taken to structure proof of concepts in such a way that they answer very specific questions and minimize ‘false failures.’ Since a technology’s full suite of features and support may not be implemented in a given proof of concept, an apparent failure of the technology may in fact be due to overly broad or ambiguous proof of concept design. Clearly define success or failure criteria of these assessments. If a technology does not meet success criteria, first ask ‘Can this issue be addressed?’ before discontinuing the use case or technology
Refine Pivot or Proceed

Based on what was learned during each assessment, re-consider the feasibility and alignment with strategy for the use case and technology selection(s). Make go/no-go decisions, pivots, or adjustments as appropriate. After each decision, refine the PT Experimentation Plan with new data, metrics, questions or hypotheses. Conduct additional follow-up testing or re-visit technology options if necessary.

 

Discussion Guide

The considerations listed here are intended to help identify risks and unknowns, plus provide a list of internal stakeholders typically able to offer insight or expertise. Please note, the provided list of considerations is not all-encompassing.

As internal department names vary greatly from one company to the next, some of the listed stakeholders may not be self-explanatory. Below, you will find a short description of the more ambiguous groups:

Internal StakeholderDescription
Clinical Technologies SMEs for clinical technologies, vendor relations and vendor management, technology scouting, implementation strategies as well as implementation leadership and guidance.
Medical Medical or clinical SMEs for given indications and/or therapeutic areas.
Patient Engagement SMEs or groups assisting with patient advisory boards, patient engagement and retention strategies, patient centricity assessments and/or patient centric strategies.
Quality SMEs for qualification, testing and validation activities, processes, (vendor) audits, documentation and GxP compliance.

Other, more universally understood, stakeholders referenced include Data Management, Functional Leadership, Human Resources, IT, Legal, Procurement, Regulatory Affairs, Site Relations and Study Teams.

Feasibility & Quality

Consideration
Internal Stakeholders
Have you weighed the benefits and drawbacks of both in-person visits and remote communication methods and agreed when each may be more appropriate?
Clinical Technologies, Patient Engagement
Have you conducted an appropriate risk assessment for use of the PT? Are risks documented accordingly and are mitigation plans in place?
Clinical Technologies, IT, Study Teams
Is the technology designed in a simple and intuitive manner or are significant patient/site support activities to be expected?
Clinical Technologies, Study Teams
Is it clearly understood what factors may impact usability of the PT or resulting data quality? Are those factors accurately accounted for/mitigated? E.g. UI design, validation checks, limitations in coverage, loss of battery, impact of device failure, local regulations prohibiting/limiting use of the technology, need for maintenance, …
Clinical Technologies
Does training material sufficiently account for differences in audience and learning style? Is training readily available for all affected parties (patients, site staff, ...)? Can previous trainings be accepted/re-used? Is enough time given for training completion?
Clinical Technologies, Regulatory Affairs
Does use of the PT have a potential impact on other technologies or outcomes measured? E.g. device weight causing fatigue, …
Clinical Technologies, Medical

Process & Strategy

Consideration
Internal Stakeholders
Are the right stakeholders involved in vendor evaluations and a go/no-go decision?
*
What scope of evaluation, procurement and contracting is appropriate for the target activity? E.g. "full blown" validation for short proof of concept vs. fit for purpose qualification.
Clinical Technologies, IT, Procurement, Study Teams
Has your company previously worked with or are you currently working with the target vendor? How successful was such a previous collaboration? Are master service level agreements in place that can be capitalized upon here?
Procurement
Are responsibilities of the involved parties clearly laid out in vendor contracts? E.g. support, maintenance, shipping, ...
Procurement
Does the vendor have a fallback plan in place for common anticipated issues? Are those issues defined and known to you as well as sites?
Study Teams
How does use of the PT affect the proposed study timelines? E.g. extended start-up time, recruitment time, …
Clinical Technologies, Patient Engagement, Site Relations, Study Teams
Are data access, monitoring and management responsibilities and processes clear for both, the PT and subsequent data stores?
Data Management, Study Teams
Are data transmission, security, return and archival processes clear to all stakeholders? E.g. backup processes, sponsor TMF, site archive, data protection on-device, …
Data Management, IT, Study Teams

Site Impact

Consideration
Internal Stakeholders
What is the impact of the PT on site burden? Should site input be gathered prior to PT use? E.g. additional time investments, training requirements, conflict with site SOPs, ease of processes, acting as support for patients, cost, site benefit outside of protocol mandated use, …
Site Relations, Study Teams

Technology & Infrastructure

Consideration
Internal Stakeholders
Will study participants need to/have the option to utilize their own devices (BYOD) or will devices have to be provisioned? If devices must be provisioned, are supply mechanisms and responsibilities clearly defined?
Clinical Technologies, Procurement, Study Teams
Will the PT require additional setup or infrastructure at sites or patient homes? E.g. configuring or calibrating devices, Wi-Fi hubs, access to patient/site Wi-Fi, cell coverage, special/secure storage, …
Clinical Technologies, IT, Study Teams

Use Case Development

Stage Definition

Conduct additional research and scoping to further develop a use case and PT experimental plan for a study or related series of studies. Define the goals and requirements for the PT use case, and determine how to approach implementation to achieve a scalable solution.

Approach

Confirm or refine the problem statement, research question, and desired value

  • Outline objectives for the PT use case based on the research question, organizational goals and strategy, and the desired benefits of the PT

Identify groups and capabilities required to support the PT program

  • Working with PT may require infrastructure or additional team members compared to traditional clinical trial design. Determine what additional expertise or support you may need (e.g., increased IT support, technology specialists, new data management or analytical capabilities, market research or user experience research capabilities), and engage with appropriate groups early in the development process

Identify and characterize internal and external stakeholders

  • Identify target users of the PT. Identify and characterize target patient demographics, therapeutic areas, geographic regions, trial phases, etc. As needed, pursue patient or caregiver engagements to further develop understanding of needs and priorities
  • Identify other stakeholders impacted by the PT use case. This may include internal stakeholders, sites, CROs, caregivers, or others
  • Consider regulatory implications of the PT and, if appropriate, engage relevant health authorities for feedback
  • Identify the drivers and barriers experienced by critical users and stakeholders, and how they may affect PT implementation. As appropriate, engage with these stakeholders to gather insights

Identify requirements for the PT and the use case (in pilot and at scale)

  • Identify endpoints, functionality, features, and data streams that will be required or desired to achieve study and program goals
  • Identify novel considerations that may impact study design or support. This may include user acceptance, IT infrastructure, data management, validation, translation, or other considerations
  • Incorporate perspectives and needs from applicable stakeholders to generate additional requirements. Perspectives can be gathered from engagements, research, past learnings, or published work

Identify potential technologies

  • Identify potential technologies, vendors, or technology development options that appear fit-for-purpose and warrant further exploration

Identify questions, gaps, unknowns, and required research

  • Identify assumptions or unknowns with regard to technical feasibility, value proposition, usability, stakeholder perspectives, regulatory considerations, implementation, and scalability. Identify those that must be addressed to meet study or program requirements
  • Identify potential challenges associated with scaling the PT from a pilot to more mainstream use
  • Identify challenges or risks to adopting PT in the program (e.g., unknowns, risks, costs, timing, stakeholder burdens) using a risk assessment tool such as FMEA. Engage the technology’s users and stakeholders as applicable

Develop a PT Experimentation Plan

  • Develop a plan for addressing unknowns, mitigating risks, and establishing the value proposition for the PT, in preparation for both pilots and scaled solutions
  • Identify which critical unknowns can be addressed through additional research, engagement with stakeholders, proof of concept testing (as described in the Technology Proof of Concept Stage), or technology pilots (as described in the Technology Pilot Stage)
  • For unknowns that can be addressed through technology proof of concept testing, develop methods and approaches to conduct such testing. Set up a process to capture learnings, and use learnings to improve future testing or piloting activities
  • Define success criteria for each phase of testing
  • Define backup plans, in case PT does not meet desired success criteria
Refine Pivot or Proceed

Based on what you learned during landscaping, research, and planning, re-evaluate the use case’s feasibility and alignment with strategy. Make go/no-go decisions, pivots, or adjustments as appropriate. After each decision, refine the use case with new landscaping, interviews, risk assessments, etc.

Discussion Guide

The considerations listed here are intended to help identify risks and unknowns, plus provide a list of internal stakeholders typically able to offer insight or expertise. Please note, the provided list of considerations is not all-encompassing.

As internal department names vary greatly from one company to the next, some of the listed stakeholders may not be self-explanatory. Below, you will find a short description of the more ambiguous groups:

Internal StakeholderDescription
Clinical Technologies SMEs for clinical technologies, vendor relations and vendor management, technology scouting, implementation strategies as well as implementation leadership and guidance.
Medical Medical or clinical SMEs for given indications and/or therapeutic areas.
Patient Engagement SMEs or groups assisting with patient advisory boards, patient engagement and retention strategies, patient centricity assessments and/or patient centric strategies.
Quality SMEs for qualification, testing and validation activities, processes, (vendor) audits, documentation and GxP compliance.

Other, more universally understood, stakeholders referenced include Data Management, Functional Leadership, Human Resources, IT, Legal, Procurement, Regulatory Affairs, Site Relations and Study Teams.

Budget & Resourcing

Consideration
Internal Stakeholders
Are sufficient resources available to support use of the PT? Are additional and/or specialist resources needed? Should these be internal or external? When evaluating existing resources, consider qualifications as well as conflicting workload.
Functional Leadership, Human Resources, Procurement
Will the PT require additions or changes to internal infrastructure or IT systems? Is this cost accounted for?
Clinical Technologies, IT
What is the expected implementation cost of the PT? Is this a onetime cost per study/at scale or will use of the PT create running costs throughout each study?
Procurement
Will use of the PT warrant or require increased monitoring? Are such additional monitoring resources available?
Human Resources, Study Teams

Feasibility & Quality

Considerations
Internal Stakeholders
Have you weighed the benefits and drawbacks of both in-person visits and remote communication methods and agreed when each may be more appropriate?
Clinical Technologies, Patient Engagement
Have you conducted an appropriate risk assessment for use of the PT? Are risks documented accordingly and are mitigation plans in place?
Clinical Technologies, IT, Study Teams
Does the planned use match with the labeled intended use of the PT? Will the PT be able to support the target purpose out of the box or is customization of the PT needed? Would such customization be futureproof? Would additional third-party vendors have to be involved?
Clinical Technologies, Study Teams
Is the technology designed in a simple and intuitive manner or are significant patient/site support activities to be expected?
Clinical Technologies, Study Teams
Is it clearly understood what factors may impact usability of the PT or resulting data quality? Are those factors accurately accounted for/mitigated? E.g. UI design, validation checks, limitations in coverage, loss of battery, impact of device failure, local regulations prohibiting/limiting use of the technology, need for maintenance, …
Clinical Technologies
Does use of the PT have a potential impact on other technologies or outcomes measured? E.g. device weight causing fatigue, …
Clinical Technologies, Medical
Has clinical validity been demonstrated between the data generated from the patient technology and the clinical outcome to be studied?
Clinical Technologies
Is the PT generally suitable for the target purpose and context or does it come with significant limitations? E.g. short battery life, lack of water resistance, too heavy, sensitivity, …
Clinical Technologies, Study Teams
Has the PT previously been used in the target context? Has performance been validated? E.g. within a clinical trial, within the target population, for submissions, for exploratory data gathering, …
Clinical Technologies, Regulatory Affairs

Legal & Regulatory

Consideration
Internal Stakeholders
Does use of the PT raise data privacy concerns or face legal or regulatory data privacy hurdles? This may apply not only to patients but also non-participants whose images, voices or other information may inadvertently be collected by the PT used or worn by patients.
Clinical Technologies, Legal, Regulatory Affairs
Is the intended implementation of the PT compliant with 21 CFR Part 11, HIPPA, GDP’s, medical device standards, …? Does the PT have a formal regulatory classification imposing additional regulations to be complied with?
Regulatory Affairs
Is use of the PT for the given purpose endorsed or opposed by regulatory authorities?
Regulatory Affairs
Could use of the PT open the company up to unusual/unexpected legal claims?
Legal
Can the PT be validated as required per GDPs guidelines? Has the PT/vendor already been validated/qualified by the company/CRO partners?
Clinical Technologies, Quality
Can the PT be deployed globally? Are there import restrictions/regulations complicating or prohibiting deployment in certain countries?
Clinical Technologies, Regulatory Affairs
Does the PT have any age restrictions to consider? E.g. legal restrictions, not suitable for kids, …
Legal, Regulatory Affairs
Will local laws and regulations impact the use of the PT at the site?
Legal, Regulatory Affairs

Process & Strategy

Consideration
Internal Stakeholders
Do you have a valid implementation strategy in place for a first proof of concept, pilot or subsequent scaled implementation?
Clinical Technologies
Are the right stakeholders involved in vendor evaluations and a go/no-go decision?
*
Is the PT specific to a given project or to be used broadly across the platform/portfolio?
Clinical Technologies, Study Teams
Are the PT and implementation strategy aligned with the overarching company strategy? E.g. insourcing vs. outsourcing, build vs. buy, …
IT
Has your company previously worked with or are you currently working with the target vendor? How successful was such a previous collaboration? Are master service level agreements in place that can be capitalized upon here?
Procurement
How does use of the PT affect the proposed study timelines? E.g. extended start-up time, recruitment time, …
Clinical Technologies, Patient Engagement, Site Relations, Study Teams
Are you early enough in the study design process to still allow for successful addition of the PT? Are the projected timelines realistic? Consider time needed for translations, manufacture, shipping, import, validation, …
Clinical Technologies, Study Teams
Is the data to be collected clearly defined, understood and can it be reconciled with other study data? Is the data accessible and attributable as required? Can data be gathered and made available in a timely enough manner?
Data Management
Are you accounting for feedback, expertise and best practices as part of your design and plans for PT use? This may include vendor expertise, industry experience and guidelines, site feedback, prior experience within your company, …
Clinical Technologies, Study Teams

Scalability & Support

Consideration
Internal Stakeholders
Can the PT be scaled up across the portfolio? Would the vendor be able to support this? E.g. number of devices that can be obtained, staff available on the vendor side, …
Clinical Technologies, Study Teams
What languages and geographies are the vendor able to support? Is this sufficient for a pilot and a scaled implementation beyond the pilot?
Clinical Technologies, Study Teams
Can the PT be maintained for the entire life of the study? E.g. replacement device availability, long term support of device and software, …
Clinical Technologies, IT, Study Teams

Site Impact

Consideration
Internal Stakeholders
What is the impact of the PT on site burden? Should site input be gathered prior to PT use? E.g. additional time investments, training requirements, conflict with site SOPs, ease of processes, acting as support for patients, cost, site benefit outside of protocol mandated use, …
Site Relations, Study Teams
What responsibilities related to mobile technologies will site staff have for data entry, clinical event identification and follow-up?
Site Relations, Study Teams
Is the support expected from sites for patients realistic or is too much being asked of them? Are sites properly trained for the support they are expected to offer?
Site Relations, Study Teams

Technology Pilot

Stage Definition

Implement the PT experimentally in the desired use case within a clinical trial or study. Gather experiential data, assess real-world feasibility of the PT, develop learnings to inform future work, and determine readiness for expansion.

Approach

A technology pilot should generate evidence supporting the feasibility of the PT for scaled use and should involve implementation of the PT in a study or trial with a targeted population of end users. When developing a pilot, teams should ensure continued alignment with the strategic goals for the technology.

Pilots can be used to validate the technology in a specific use-case, assess real-world functionality or adherence, test and refine training procedures, collect data for algorithm development, or support the development of a business case. Pilots may focus on specific aspects of implementation or may test implementation of the PT comprehensively as it is desired to be used at scale.

Types of Pilots (Not mutually exclusive)

  • Validation Study – A study to prove that the PT is accurately measuring the outcomes it was intended to measure according to GxP requirements. Some PT may require validation for new use cases, implementation methods, or patient populations
  • Equivalency Study – A study to prove that the endpoints measured by the PT are equivalent to the endpoints measured by traditional means
  • Feasibility Study – A pre-clinical or clinical technology study conducted with end-users outside of an interventional drug trial, designed to assess the feasibility of an implementation strategy
  • Modified or In-Clinic Technology Assessment – In some cases, the PT is intended to be used in a home setting but questions about the use case or the technology’s validity remain. In these cases, the PT may be used initially during a clinic visit to generate supporting information
  • Experimental or Limited Implementation in a Clinical Trial – A pilot could be run as a standalone trial or as an exploratory arm of a larger a Phase 1, 2, 3, or 4 trial (potentially with a limited number of sites or in a sub-set of a trial population). Any data or endpoints generated by the PT could be categorized as experimental

Pilot Design

  • Identify expected outcomes, success measures and Go/No-Go criteria for advancing to Expansion Stage (Referencing strategic priorities and past learnings). Plan pilot and data collection such that major risks or questions about the technology’s scalability can be answered in a data-driven fashion, building from outcomes of technology proof of concepts and previous work
  • Ensure realistic timelines are developed to allow for activities that may require additional lead times (regulatory engagement, procurement and distribution of the PT, training, development of tech support strategy, etc.)
  • Identify and incorporate metrics that speak to the desired outcomes, success measures, and strategic priorities. Incorporate mechanisms for gathering stakeholder, patient, and other user feedback
  • Consider regulatory implications of the PT and, if appropriate, engage relevant health authorities for feedback. Considerations that may impact regulatory strategy include:
    • What is the original intended use of the PT? Does the use case differ from this intended use?
    • Does the PT have formal regulatory classification (i.e., is it a medical device)?
    • Will the PT be used solely in a clinical trial setting, or also in the commercial space?
    • Is the PT specific to a project or is it intended to be used across a platform?

Pilot Conduct

  • Conduct pilot and collect data on PT use
  • Collect feedback on PT usability and implementation from sites, patients, and other stakeholders

Pilot Retrospective

  • Analyze data and compare outcomes to success criteria
  • Document and share learnings, both positive and negative. Provide feedback or insights that may impact strategy or future work, inclusive of patient feedback as appropriate
Refine Pivot or Proceed

Based on what was learned during the pilot, assess the technology’s or use case’s feasibility, value, and alignment with strategy. Make go/no-go decisions, pivots, or adjustments as appropriate. After each decision, refine the PT Experimentation Plan with new data, metrics, questions or hypotheses. Conduct additional Proof of Concept testing or re- visit technology options if necessary. If applicable, develop and refine business case, roadmap or risk analysis for additional pilots or for expansion.

Discussion Guide

The considerations listed here are intended to help identify risks and unknowns, plus provide a list of internal stakeholders typically able to offer insight or expertise. Please note, the provided list of considerations is not all-encompassing.

As internal department names vary greatly from one company to the next, some of the listed stakeholders may not be self-explanatory. Below, you will find a short description of the more ambiguous groups:

Internal StakeholderDescription
Clinical Technologies SMEs for clinical technologies, vendor relations and vendor management, technology scouting, implementation strategies as well as implementation leadership and guidance.
Medical Medical or clinical SMEs for given indications and/or therapeutic areas.
Patient Engagement SMEs or groups assisting with patient advisory boards, patient engagement and retention strategies, patient centricity assessments and/or patient centric strategies.
Quality SMEs for qualification, testing and validation activities, processes, (vendor) audits, documentation and GxP compliance.

Other, more universally understood, stakeholders referenced include Data Management, Functional Leadership, Human Resources, IT, Legal, Procurement, Regulatory Affairs, Site Relations and Study Teams.

Budget & Resourcing

Consideration
Internal Stakeholders
Are sites sufficiently reimbursed for their time (e.g. additional time spent training patients)?
Site Relations, Study Teams

Feasibility & Quality

Consideration
Internal Stakeholder
Have you weighed the benefits and drawbacks of both in-person visits and remote communication methods and agreed when each may be more appropriate?
Clinical Technologies, Patient Engagement
Have you conducted an appropriate risk assessment for use of the PT? Are risks documented accordingly and are mitigation plans in place?
Clinical Technologies, IT, Study Teams
Is the technology designed in a simple and intuitive manner or are significant patient/site support activities to be expected?
Clinical Technologies, Study Teams
Does training material sufficiently account for differences in audience and learning style? Is training readily available for all affected parties (patients, site staff, ...)? Can previous trainings be accepted/re-used? Is enough time given for training completion?
Clinical Technologies, Regulatory Affairs
Does use of the PT have a potential impact on other technologies or outcomes measured? E.g. device weight causing fatigue, …
Clinical Technologies, Medical
Has clinical validity been demonstrated between the data generated from the patient technology and the clinical outcome to be studied?
Clinical Technologies
Is the PT generally suitable for the target purpose and context or does it come with significant limitations? E.g. short battery life, lack of water resistance, too heavy, sensitivity, …
Clinical Technologies, Study Teams
Has the PT previously been used in the target context? Has performance been validated? E.g. within a clinical trial, within the target population, for submissions, for exploratory data gathering, …
Clinical Technologies, Regulatory Affairs

Legal & Regulatory

Consideration
Internal Stakeholders
Does use of the PT raise data privacy concerns or face legal or regulatory data privacy hurdles? This may apply not only to patients but also non-participants whose images, voices or other information may inadvertently be collected by the PT used or worn by patients.
Clinical Technologies, Legal, Regulatory Affairs
Is the intended implementation of the PT compliant with 21 CFR Part 11, HIPPA, GDPs, medical device standards, …? Does the PT have a formal regulatory classification imposing additional regulations to be complied with?
Regulatory Affairs
Is use of the PT for the given purpose endorsed or opposed by regulatory authorities?
Regulatory Affairs
Can the PT be deployed globally? Are there import restrictions/regulations complicating or prohibiting deployment in certain countries?
Clinical Technologies, Regulatory Affairs
Does the PT have any age restrictions to consider? E.g. legal restrictions, not suitable for kids, …
Legal, Regulatory Affairs
Will local laws and regulations impact the use of the PT at the site?
Legal, Regulatory Affairs

Process & Strategy

Consideration
Internal Stakeholders
Are you following all applicable SOPs? Are the SOPs fit for purpose?
Quality
Are the PT and implementation strategy aligned with the overarching company strategy? E.g. insourcing vs. outsourcing, build vs. buy, …
IT
Has your company previously worked with or are you currently working with the target vendor? How successful was such a previous collaboration? Are master service level agreements in place that can be capitalized upon here?
Procurement
Are responsibilities of the involved parties clearly laid out in vendor contracts? E.g. support, maintenance, shipping, ...
Procurement
Does the vendor have a fallback plan in place for common anticipated issues? Are those issues defined and known to you as well as sites?
Study Teams
How does use of the PT affect the proposed study timelines? E.g. extended start-up time, recruitment time, …
Clinical Technologies, Patient Engagement, Site Relations, Study Teams
Are you early enough in the study design process to still allow for successful addition of the PT? Are the projected timelines realistic? Consider time needed for translations, manufacture, shipping, import, validation, …
Clinical Technologies, Study Teams
Are data access, monitoring and management responsibilities and processes clear for both, the PT and subsequent data stores?
Data Management, Study Teams
Are data transmission, security, return and archival processes clear to all stakeholders? E.g. backup processes, sponsor TMF, site archive, data protection on-device, …
Data Management, IT, Study Teams
Are you accounting for feedback, expertise and best practices as part of your design and plans for PT use? This may include vendor expertise, industry experience and guidelines, site feedback, prior experience within your company, …
Clinical Technologies, Study Teams

Scalability & Support

Consideration
Internal Stakeholder
Can the PT be maintained for the entire life of the study? E.g. replacement device availability, long term support of device and software, …
Clinical Technologies, IT, Study Teams
Is technical/user support readily available for patients and sites if needed? This includes considerations of time (24/7 support) and multi-language support in global studies. Is support personnel sufficiently trained not only on the technology but also on study specifics, to avoid potential false recommendations?
Study Teams

Technology & Infrastructure

Consideration
Internal Stakeholders
Will study participants need to/have the option to utilize their own devices (BYOD) or will devices have to be provisioned? If devices must be provisioned, are supply mechanisms and responsibilities clearly defined?
Clinical Technologies, Procurement, Study Teams
Will the PT require additional setup or infrastructure at sites or patient homes? E.g. configuring or calibrating devices, Wi-Fi hubs, access to patient/site Wi-Fi, cell coverage, special/secure storage, …
Clinical Technologies, IT, Study Teams

Expansion

Stage Definition

Develop and implement a strategy for the scaled implementation of PT across studies, programs, therapeutic areas, and geographies, based on learnings from each of the previous stages.

Approach

Identify target use cases and populations

  • Determine the desired scope for the use of PT at scale. Some PT may be appropriate for use with all patients, while others may only be appropriate or effective for certain sub-populations
  • Assess the level of difficulty with which the PT can be implemented across different geographies, therapeutic areas, or populations. This could be based on the regulatory environment, language, population acceptance of technology, or other factors
  • Prioritize potential use cases, geographies, therapeutic areas, or populations, and develop plan for scaling to them over time

Develop business case and/or value proposition

  • Identify specific factors or measures that speak to the value of the PT. Provide guidance on how to monitor these factors across studies, and to assess the value of the PT over time
  • If necessary or possible, estimate scale required to generate the desired returns outlined in the PT strategy

Address potential issues identified during technology proof of concepts or pilots

  • Ensure the PT and its use case(s) are feasible for all stakeholders. If the pilot produced findings around patient, site, or other stakeholder burden, take steps to address them
  • If additional technical capabilities, infrastructure, data streams or features are required for scaled implementation, create a plan to develop them
  • Re-evaluate previously identified risks. Ensure they have been mitigated, or that mitigation plans are in place

Consider and document factors influencing future study planning

  • Understand impacts on budget and timeline: Based on previous work and ongoing engagement with providers, model or estimate the impacts of the PT on study start-up costs, lead time, and overall study timeline. Consider potential economies of scale, and identify up-front costs associated with growing the PT and infrastructure
  • Understand regional or geographical considerations: Factors associated with scaled implementation may include regional variation in regulations, translation requirements, local characteristics of infrastructure or supply chain, and cultural differences impacting PT use
  • Solidify data management, storage, and reporting plans at scale: Ensure vendors and systems have all necessary capabilities to support the particular study, and ensure internal teams and systems have all necessary capabilities to manage this data
Discussion Guide

The considerations listed here are intended to help identify risks and unknowns, plus provide a list of internal stakeholders typically able to offer insight or expertise. Please note, the provided list of considerations is not all-encompassing.

As internal department names vary greatly from one company to the next, some of the listed stakeholders may not be self-explanatory. Below, you will find a short description of the more ambiguous groups:

Internal StakeholderDescription
Clinical Technologies SMEs for clinical technologies, vendor relations and vendor management, technology scouting, implementation strategies as well as implementation leadership and guidance.
Medical Medical or clinical SMEs for given indications and/or therapeutic areas.
Patient Engagement SMEs or groups assisting with patient advisory boards, patient engagement and retention strategies, patient centricity assessments and/or patient centric strategies.
Quality SMEs for qualification, testing and validation activities, processes, (vendor) audits, documentation and GxP compliance.

Other, more universally understood, stakeholders referenced include Data Management, Functional Leadership, Human Resources, IT, Legal, Procurement, Regulatory Affairs, Site Relations and Study Teams.

Budget & Resourcing

Consideration
Internal Stakeholder
Are sites sufficiently reimbursed for their time (e.g. additional time spent training patients)?
Site Relations, Study Teams

Feasibility & Quality

Consideration
Internal Stakeholders
Have you conducted an appropriate risk assessment for use of the PT? Are risks documented accordingly and are mitigation plans in place?
Clinical Technologies, IT, Study Teams
Does training material sufficiently account for differences in audience and learning style? Is training readily available for all affected parties (patients, site staff, ...)? Can previous trainings be accepted/re-used? Is enough time given for training completion?
Clinical Technologies, Regulatory Affairs
Does use of the PT have a potential impact on other technologies or outcomes measured? E.g. device weight causing fatigue, …
Clinical Technologies, Medical
Has clinical validity been demonstrated between the data generated from the patient technology and the clinical outcome to be studied?
Clinical Technologies
Is the PT generally suitable for the target purpose and context or does it come with significant limitations? E.g. short battery life, lack of water resistance, too heavy, sensitivity, …
Clinical Technologies, Study Teams
Has the PT previously been used in the target context? Has performance been validated? E.g. within a clinical trial, within the target population, for submissions, for exploratory data gathering, …
Clinical Technologies, Regulatory Affairs

Legal & Regulatory

Consideration
Internal Stakeholders
Does use of the PT raise data privacy concerns or face legal or regulatory data privacy hurdles? This may apply not only to patients but also non-participants whose images, voices or other information may inadvertently be collected by the PT used or worn by patients.
Clinical Technologies, Legal, Regulatory Affairs
Is the intended implementation of the PT compliant with 21 CFR Part 11, HIPPA, GDPs, medical device standards, …? Does the PT have a formal regulatory classification imposing additional regulations to be complied with?
Regulatory Affairs
Is use of the PT for the given purpose endorsed or opposed by regulatory authorities?
Regulatory Affairs
Can the PT be deployed globally? Are there import restrictions/regulations complicating or prohibiting deployment in certain countries?
Clinical Technologies, Regulatory Affairs
Does the PT have any age restrictions to consider? E.g. legal restrictions, not suitable for kids, …
Legal, Regulatory Affairs
Will local laws and regulations impact the use of the PT at the site?
Legal, Regulatory Affairs

Process & Strategy

Consideration
Internal Stakeholders
Are you following all applicable SOPs? Are the SOPs fit for purpose?
Quality
Are the PT and implementation strategy aligned with the overarching company strategy? E.g. insourcing vs. outsourcing, build vs. buy, …
IT
How does use of the PT affect the proposed study timelines? E.g. extended start-up time, recruitment time, …
Clinical Technologies, Patient Engagement, Site Relations, Study Teams
Are you early enough in the study design process to still allow for successful addition of the PT? Are the projected timelines realistic? Consider time needed for translations, manufacture, shipping, import, validation, …
Clinical Technologies, Study Teams
Are you accounting for feedback, expertise and best practices as part of your design and plans for PT use? This may include vendor expertise, industry experience and guidelines, site feedback, prior experience within your company, …
Clinical Technologies, Study Teams

Scalability & Support

Consideration
Internal Stakeholder
Can the PT be scaled up across the portfolio? Would the vendor be able to support this? E.g. number of devices that can be obtained, staff available on the vendor side, …
Clinical Technologies, Study Teams
What languages and geographies are the vendor able to support? Is this enough for a pilot and a scaled implementation beyond the pilot?
Clinical Technologies, Study Teams
Can the PT be maintained for the entire life of the study? E.g. replacement device availability, long term support of device and software, …
Clinical Technologies, IT, Study Teams
Is technical/user support readily available for patients and sites if needed? This includes considerations of time (24/7 support) and multi-language support in global studies. Is support personnel sufficiently trained not only on the technology but also on study specifics, to avoid potential false recommendations?
Study Teams

Technology & Infrastructure

Consideration
Internal Stakeholders
Will study participants need to/have the option to utilize their own devices (BYOD) or will devices have to be provisioned? If devices must be provisioned, are supply mechanisms and responsibilities clearly defined?
Clinical Technologies, Procurement, Study Teams
Will the PT require additional setup or infrastructure at sites or patient homes? E.g. configuring or calibrating devices, Wi-Fi hubs, access to patient/site Wi-Fi, cell coverage, special/secure storage, …
Clinical Technologies, IT, Study Teams